BioWorld

April 25, 2005

Lifted By Higher Product Sales, Amgen Beats Consensus EPS

Beating Wall Street estimates, Amgen Inc. performed well in the first quarter, reporting strong revenue for most of its products, despite Medicare reimbursement changes. (BioWorld Today) Read More

Solexa Signs Deal To Raise $32.5M, Advance Platform

Novel Approach To Synthesis Causing Tetracycline Variety

Recent Stem Cell Bill Forbids Human Reproductive Cloning

Hamilton Pharmaceuticals' First Financing: $11M For CNS Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.

Wuxi Apptec insists it’s ‘not a Chinese military company’

BioWorld

Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...